Precigen, Inc.(PGEN)Earnings, Financials & Key RatiosPrecigen, Inc. (PGEN) stock price & volume — 10-year historical chart
Investment Thesis • Updated 2026Q1
suggesting that the current capital structure is unsustainable without further external financing.
Precigen, Inc. (PGEN) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Precigen, Inc. (PGEN) EPS & revenue vs analyst estimates — last 4 quarters
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 13, 2026 | $0.02vs $0.03+33.3% | $23Mvs $21M+11.8% |
| Q2 2026 | Mar 25, 2026 | $0.01vs $0.10+90.0% | $5Mvs $8M-45.6% |
| Q4 2025 | Nov 13, 2025 | $0.11vs $0.08-37.5% | $3Mvs $8M-64.7% |
| Q3 2025 | Aug 12, 2025 | $0.11vs $0.14+21.4% | $856,000vs $933,330-8.3% |
Recent stock market news and headlines for Precigen, Inc. (PGEN)
Precigen earns a STRONG BUY rating following the commercial success of PAPZIMEOS and rapid revenue growth. PGEN's AdenoVerse platform underpins a validated, scalable franchise, with PAPZIMEOS now endorsed as first-line therapy for RRP and covered by major US insurers. Management projects cash flow breakeven in 2026, with Wall Street revising EPS and revenue estimates sharply since the 1Q earnings call.
Key metrics vs top competitors for Precigen, Inc. (PGEN)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $5.51 | $1.66B | -3.91 | 146.73% | -2588.21% | -843.57% | — | |
| $3.02 | $352.01M | -2.63 | -51.24% | -2056.79% | -58.89% | — | |
| $23.24 | $2.05B | -7.06 | 627.84% | -112.01% | -256.66% | — | |
| $3.50 | $145.75M | -1029.41 | 10.37% | 52.16% | — | — | |
| $5.29 | $10.32M | -0.46 | -13.43% | -299.66% | — | — | |
| $40.09 | $8.23B | -14.47 | — | — | -68.16% | — |
Precigen, Inc. (PGEN) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Precigen, Inc. (PGEN) SEC filings — annual & quarterly reports (10-K, 10-Q)
May 13, 2026·SEC
Mar 25, 2026·SEC
Nov 13, 2025·SEC
Get notified when PGEN posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Precigen, Inc. (PGEN) stock FAQ — growth, dividends, profitability & financials explained
Precigen, Inc. (PGEN) reported $31.6M in revenue for fiscal year 2025. This represents a 294% increase from $8.0M in 2011.
Precigen, Inc. (PGEN) grew revenue by 146.7% over the past year. This is strong growth.
Precigen, Inc. (PGEN) reported a net loss of $204.4M for fiscal year 2025.
Precigen, Inc. (PGEN) has a return on equity (ROE) of -843.6%. Negative ROE indicates the company is unprofitable.
Precigen, Inc. (PGEN) had negative free cash flow of $117.6M in fiscal year 2025, likely due to heavy capital investments.
